
Marlene P Freeman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8469358/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Course of ADHD during Pregnancy. Journal of Attention Disorders, 2022, 26, 143-148.	2.6	4
2	Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics. Archives of Women's Mental Health, 2022, 25, 511-516.	2.6	4
3	Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Archives of Women's Mental Health, 2022, 25, 313-326.	2.6	13
4	Body dissatisfaction and disordered eating in the perinatal period: an underrecognized high-risk timeframe and the opportunity to intervene. Archives of Women's Mental Health, 2022, 25, 739-751.	2.6	5
5	Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of Women's Mental Health, 2021, 24, 659-667.	2.6	8
6	Investigational Treatment of Depressive Disorders With Neuroactive Steroids. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0
7	Reproductive Safety of Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2021, 82, .	2.2	7
8	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. European Neuropsychopharmacology, 2021, 49, 122-132.	0.7	17
9	Perinatal depression screening using smartphone technology: Exploring uptake, engagement and future directions for the MGH Perinatal Depression Scale (MGHPDS). PLoS ONE, 2021, 16, e0257065.	2.5	3
10	Perinatal experiences of pregnant women with psychiatric disorders during the COVID-19 pandemic. General Hospital Psychiatry, 2021, 73, 114-119.	2.4	2
11	Postpartum depression screening: Treatment engagement, barriers to care, and change in depressive symptoms. , 2021, 33, e2-e9.		1
12	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	7.9	235
13	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders, 2020, 260, 131-139.	4.1	21
14	Impact of Estradiol Variability and Progesterone on Mood in Perimenopausal Women With Depressive Symptoms. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e642-e650.	3.6	27
15	Relapse Prevention After Recovery in Patients With Persistent Major Depressive Disorder—An Active Pursuit. JAMA Psychiatry, 2020, 77, 231.	11.0	6
16	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 287-292.	1.4	25
17	A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. Journal of Affective Disorders, 2020, 265, 233-238.	4.1	12
18	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depression and Anxiety, 2020, 37, 485-495.	4.1	9

MARLENE P FREEMAN

#	Article	IF	CITATIONS
19	The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative. Menopause, 2020, 27, 1117-1125.	2.0	9
20	Omega-3 Fatty Acid Supplementation for Perinatal Depression and Other Subpopulations?. Journal of Clinical Psychiatry, 2020, 81, .	2.2	4
21	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 82, .	2.2	6
22	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research, 2019, 110, 166-171.	3.1	41
23	International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychotherapy and Psychosomatics, 2019, 88, 263-273.	8.8	114
24	The impact of obesity on pregnancy outcomes among women with psychiatric disorders: Results from a prospective pregnancy registry. Journal of Psychosomatic Research, 2019, 123, 109735.	2.6	2
25	Deception and Study Participation—Unintended Influences and Ramifications for Clinical Trials. JAMA Network Open, 2019, 2, e187359.	5.9	0
26	28 How is Postpartum Depression Currently Diagnosed and Managed? Insights from a Virtual Patient Simulation. CNS Spectrums, 2019, 24, 189-190.	1.2	1
27	Perinatal Depression. JAMA - Journal of the American Medical Association, 2019, 321, 550.	7.4	18
28	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). Journal of Clinical Psychiatry, 2019, 80, .	2.2	32
29	Tachyphylaxis in major depressive disorder: A review of the current state of research. Journal of Affective Disorders, 2019, 245, 488-497.	4.1	23
30	A prenatal supplement with methylfolate for the treatment and prevention of depression in women trying to conceive and during pregnancy. Annals of Clinical Psychiatry, 2019, 31, 4-16.	0.6	8
31	Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. Psychosomatics, 2018, 59, 125-134.	2.5	9
32	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation, 2018, 11, 75-84.	1.6	20
33	Course of major depressive disorder after pregnancy and the postpartum period. Depression and Anxiety, 2018, 35, 1130-1136.	4.1	6
34	Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. General Hospital Psychiatry, 2018, 53, 73-79.	2.4	29
35	Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. American Journal of Psychiatry, 2018, 175, 1225-1231.	7.2	28
36	Management of Attention Deficit Hyperactivity Disorder During Pregnancy. Obstetrics and Gynecology Clinics of North America, 2018, 45, 495-509.	1.9	11

Marlene P Freeman

#	Article	IF	CITATIONS
37	Predictors of Depressive Relapse in Women Undergoing Infertility Treatment. Journal of Women's Health, 2018, 27, 1408-1414.	3.3	13
38	Guarding the Gate. Journal of Clinical Psychopharmacology, 2017, 37, 176-181.	1.4	22
39	Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. Journal of Psychiatric Research, 2017, 95, 84-90.	3.1	24
40	Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant. Annals of Clinical Psychiatry, 2017, 29, 28-34.	0.6	2
41	Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Annals of Clinical Psychiatry, 2017, 29, 249-257.	0.6	10
42	Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. International Clinical Psychopharmacology, 2016, 31, 100-109.	1.7	7
43	Implementation of universal screening for depression during pregnancy: feasibility and impact on obstetric care. American Journal of Obstetrics and Gynecology, 2016, 215, 517.e1-517.e8.	1.3	67
44	Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3847-3855.	3.6	50
45	Adverse Effects in the Pharmacologic Management of Bipolar Disorder During Pregnancy. Psychiatric Clinics of North America, 2016, 39, 465-475.	1.3	12
46	Does folic acid interfere with lamotrigine?. Lancet Psychiatry, the, 2016, 3, 704-705.	7.4	4
47	Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Archives of Women's Mental Health, 2016, 19, 437-441.	2.6	13
48	Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. American Journal of Psychiatry, 2016, 173, 263-270.	7.2	162
49	<scp>I</scp> nternational <scp>S</scp> ociety for <scp>N</scp> utritional <scp>P</scp> sychiatry <scp>R</scp> esearch consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry, 2015, 14, 370-371.	10.4	81
50	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depression and Anxiety, 2015, 32, 605-613.	4.1	34
51	The Role of Anger/Hostility in Treatment-Resistant Depression. Journal of Nervous and Mental Disease, 2015, 203, 762-768.	1.0	19
52	Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry, the, 2015, 2, 271-274.	7.4	375
53	Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia. Annals of Clinical Psychiatry, 2015, 27, 197-202.	0.6	7
54	Omega-3 Fatty Acids and Gestational Length in a High-Risk Psychiatric Population Due to Psychiatric Morbidity and Medication Exposure During Pregnancy. Journal of Clinical Psychopharmacology, 2014, 34, 627-632.	1.4	3

MARLENE P FREEMAN

#	Article	IF	CITATIONS
55	Pharmacotherapy for Mood Disorders in Pregnancy. Journal of Clinical Psychopharmacology, 2014, 34, 244-255.	1.4	157
56	Complementary and alternative medicine therapies for perinatal depression. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 85-95.	2.8	72
57	Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. Maturitas, 2013, 75, 170-174.	2.4	20
58	Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials. Journal of Clinical Psychiatry, 2013, 74, 1018-1021.	2.2	3
59	Assisted reproduction and risk of depressive relapse: considerations for treatment. Annals of Clinical Psychiatry, 2013, 25, 283-8.	0.6	7
60	Complementary and Alternative Medicine for Psychiatrists. Canadian Journal of Psychiatry, 2012, 57, 395-396.	1.9	3
61	Omega-3 fatty acids for major depressive disorder associated with the menopausal transition. Menopause, 2011, 18, 279-284.	2.0	44
62	LC–MS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase. Chromatographia, 2011, 73, 749-754.	1.3	7
63	When She Says "No―to Medication: Psychotherapy for Antepartum Depression. Current Psychiatry Reports, 2011, 13, 459-466.	4.5	18
64	Omega-3 Fatty Acids and Depression: From Cellular Mechanisms to Clinical Care. Journal of Clinical Psychiatry, 2011, 72, 258-259.	2.2	40
65	Supportive psychotherapy for perinatal depression: preliminary data for adherence and response. Depression and Anxiety, 2010, 27, 39-45.	4.1	29
66	Psychiatric Illness during Pregnancy and the Postpartum Period. , 2010, , 613-628.		0
67	Treatment of Mood Disorders During Pregnancy and Postpartum. Psychiatric Clinics of North America, 2010, 33, 273-293.	1.3	84
68	Complementary and Alternative Medicine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 669-681.	2.2	106
69	Complementary and Alternative Medicine for Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 682-688.	2.2	56
70	Complementary and alternative medicine for perinatal depression. Journal of Affective Disorders, 2009, 112, 1-10.	4.1	51
71	Breastfeeding and Antidepressants: Clinical Dilemmas and Expert Perspectives. Journal of Clinical Psychiatry, 2009, 70, 291-292.	2.2	5
72	Managing Depression During Pregnancy. Journal of Clinical Psychiatry, 2009, 70, e25.	2.2	3

MARLENE P FREEMAN

#	Article	IF	CITATIONS
73	Postpartum Depression Treatment and Breastfeeding. Journal of Clinical Psychiatry, 2009, 70, e35.	2.2	9
74	Complementary and Alternative Medicine (CAM). Journal of Clinical Psychiatry, 2009, 70, 4-6.	2.2	102
75	Omega-3 Fatty Acids in Major Depressive Disorder. Journal of Clinical Psychiatry, 2009, 70, 7-11.	2.2	45
76	Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study. Journal of Affective Disorders, 2008, 110, 142-148.	4.1	167
77	Women and Major Depressive Disorder: Clinical Perspectives on Causal Pathways. Journal of Women's Health, 2008, 17, 1583-1590.	3.3	90
78	Pharmacokinetics of Sertraline Across Pregnancy and Postpartum. Journal of Clinical Psychopharmacology, 2008, 28, 646-653.	1.4	59
79	Antenatal Depression: Navigating the Treatment Dilemmas. American Journal of Psychiatry, 2007, 164, 1162-1165.	7.2	33
80	Lithium: Clinical Considerations in Internal Medicine. American Journal of Medicine, 2006, 119, 478-481.	1.5	106
81	An open trial of Omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatrica, 2006, 18, 21-24.	2.1	42
82	Escitalopram for Perimenopausal Depression: An Open-Label Pilot Study. Journal of Women's Health, 2006, 15, 857-861.	3.3	18
83	Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry. Journal of Clinical Psychiatry, 2006, 67, 1954-1967.	2.2	597
84	Selected integrative medicine treatments for depression: considerations for women. Journal of the American Medical Women's Association, 2004, 59, 216-24.	0.3	5
85	Omega-3 fatty acids. Evidence - Based Integrative Medicine, 2003, 1, 43-49.	0.2	2
86	The Impact of Reproductive Events on the Course of Bipolar Disorder in Women. Journal of Clinical Psychiatry, 2002, 63, 284-287.	2.2	229